B+
Bull case
25%
Probability
Target price
$5.50
+157.0% vs current
IMNN
ImunonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$2.30
+7.5% vs current
B-
Bear case
30%
Probability
Target price
$1.00
-53.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+75.9
Score
AI commentary
This T+3 follow-up remains a tentative, cautious monitoring thesis rather than a clean post-earnings upgrade. Primary sources confirmed the earnings release, continued OVATION 3 progress, stronger final Phase 2 survival framing, and an FDA-aligned Phase 3 path, but they also confirmed a $4.8 million cash balance and ongoing substantial-doubt language [#8-K-2026-05-12][#10-Q-2026-05-12]. Using checked market data, IMNN closed at $2.73 on May 11, 2026 before the release and $2.55 on May 14, 2026, indicating a roughly 6.6% decline into T+2/T+3, which suggests investors remained focused on financing risk over clinical messaging. No trustworthy delayed analyst revision set was available from checked sources, and the available peer candidates are loose same-sector micro-cap comparators rather than direct program peers, so confidence stays limited.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-31catalystPost-earnings cash burn keeps financing risk front and centerHigh impact
The Q1 2026 earnings release and 10-Q showed $4.8 million of cash at March 31, 2026, net cash used in operations of $4.0 million for the quarter, and continuing substantial-doubt language, while the 10-Q also says no ATM shares were sold in Q1 but about $0.4 million was raised after quarter-end; that leaves a likely financing or further ATM overhang as the most immediate stock driver [#8-K-2026-05-12][#10-Q-2026-05-12].
2026-09-30eventOVATION 3 enrollment progress is the next operational checkpointHigh impact
Management said on May 12 that OVATION 3 enrollment continues ahead of plan, and the 10-Q states that seven sites were open to recruitment as of March 31, 2026 with up to 43 additional sites under consideration and ITT enrollment on track to complete in the first half of 2029; a credible site-expansion or enrollment update would be the cleanest near-term de-risking signal [#8-K-2026-05-12][#10-Q-2026-05-12].
2029-06-30catalystPhase 3 execution remains the only credible rerating pathHigh impact
The May 12 earnings press release reiterated that FDA has reviewed and aligned with the Phase 3 protocol and confirmed a path to BLA filing, while updated Phase 2 data showed a 14.7-month median overall-survival improvement versus standard of care; however, the enrollment timeline now extends to the first half of 2029, so the upside case still depends on multi-year execution rather than a near-term registrational readout [#8-K-2026-05-12][#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology